Drugs
Conditions
News and resources
MIMS Supported ResourcesPromising results for early Alzheimer's drug
Trial data show that lecanemab reduced brain amyloid levels and was associated with moderately less cognitive and functional decline than placebo at 18 months.
To continue enjoying this article, please sign in. You can register for free for limited further access, or subscribe now for full access to all our content. View our subscription and registration options.